·
·
·
·
Edward von Roy
41236 Mönchengladbach
GERMANY
·
The Honourable Marjorie Michel, P.C., M.P.
Minister of Health
House of Commons
Ottawa, Ontario K1A 0A6
CANADA
Via e-mail: 25.08.2026 04:00 [ hcminister.ministresc @ hc-sc.gc.ca ] (Health Canada · Santé Canada), 25.08.2026 04:00 [ brdd.ora @ hc-sc.gc.ca ] (Biologic and Radiopharmaceutical Drugs Directorate (BRDD), Office of Regulatory Affairs (ORA))
·
25.08.2026
·
Formal Inquiry Regarding the Investigational mRNA Influenza Vaccine mFlusiva (mRNA-1010) and Public Health Safety
Dear Minister Michel,
I am writing to you to formally submit a comprehensive catalogue of technical and safety-related inquiries regarding the investigational mRNA-based influenza vaccine, mFlusiva (also designated as mRNA-1010). Given the critical role of Health Canada in safeguarding public health and evaluating novel therapeutic modalities, the pharmacological, toxicological, and structural properties of this product are of utmost public interest.
The attached questions address fundamental aspects of product design, including codon optimization, translation dynamics, lipid nanoparticle (LNP) toxicity, and biodistribution, as well as potential potential long-term cellular effects as well as foreseeable damage to tissues, organs, and life.
As a matter of transparency and informed consent, I respectfully request that these queries be reviewed by the appropriate regulatory and scientific bodies within your portfolio, such as the Health Products and Food Branch (HPFB), and the Public Health Agency of Canada (PHAC), and that a formal response be provided.
Unless the answers to the “66 questions about mFlusiva” are available, neither a medical consultation worthy of the name nor informed consent from the injection recipient is possible. Please do your utmost to ensure the answers are available, or halt mFlusiva as long as these essential questions remain open.
Thank you for your time, leadership, and dedication to the health and safety of the Canadian population.
Yours sincerely,
Edward von Roy
Graduate Social Worker, University of Applied Sciences (Diplom-Sozialarbeiter / Sozialpädagoge, FH)
·
·
·
·
66 Questions about mFlusiva
1 ► The investigational substance mFlusiva (mRNA-1010) contains the genetic blueprints (mod-mRNA) for the hemagglutinin (HA) surface proteins of precisely three different influenza virus strains. Does mFlusiva contain bacterial DNA or plasmids?
2 ► In the development of mFlusiva, did the manufacturer take into account that the tRNA distribution and availability vary across different human organs?
3 ► How does Moderna describe the role of chaperones (protein folding helpers) in relation to mFlusiva?
4 ► How has the toxic foreign protein – which forms in an unknown number of body cells following treatment with mFlusiva and represents an approximation of the hemagglutinin (HA) surface proteins of three different influenza strains – been analyzed and evaluated by Moderna during Phases I, II, and III using cryo-electron microscopy (cryo-EM), X-ray crystallography, or NMR spectroscopy?
5 ► Will mFlusiva lead to protein misfolding, thereby cluttering cells with inclusion bodies or causing diseases associated with protein aggregation, similar to Alzheimer’s or Parkinson’s disease?
6 ► Are retention samples available from all phases of the development of mFlusiva?
7 ► What has Moderna disclosed to date regarding codon optimization for mFlusiva?
8 ► Codons must be suitable for the respective organism (cf. GenScript Codon Usage Frequency Table/chart). What methodology did Moderna apply during the codon optimization process?
9 ► Every codon optimization also alters translation speed, which subsequently modifies protein folding. Has this phenomenon been investigated?
10 ► Did the manufacturer comprehend and account for the interrelated dynamics and interplay between codons and transfer RNA (tRNA)?
11 ► Will it be clarified to the public that within hours, mFlusiva reaches all lymph nodes, the entire endothelium (vascular lining), the brain, spinal cord, myocardium, kidneys, liver, lungs, bone marrow, ovaries (female), prostate (male), salivary glands, skin, spleen, testes (male), thymus, thyroid, and uterus (female) in treated (“vaccinated”) individuals, and that in principle, every cell presenting the manufactured pseudo-surface protein and its waste products – thus representing foreign proteins – will be destroyed in the subsequent immune attack, including myocardial cells, brain tissue cells, endothelial cells, or stem cells?
12 ► Are human stem cells destroyed by mFlusiva?
13 ► Capillaries are the smallest blood vessels, measuring only about 0.5 mm in length with a diameter of just 5 to 10 µm. They form a delicate network within body organs and tissues, facilitating substance exchange between blood and tissue. How is it ensured that the four lipid nanoparticle (LNP) components in mFlusiva – namely the ionizable cationic lipid SM-102 (Ionizable Amino Lipid), the PEGylated lipid DMG-PEG 2000, the helper phospholipid DSPC, and cholesterol – remain within their intended nano-size scale and do not potentially fuse into larger lipid droplets within the body, such as inside the capillaries?
14 ► What is the half-life of the lipid nanoparticle components of mFlusiva in the human body? How rapidly are they degraded, metabolized, or excreted?
15 ► How many lipid nanoparticles (LNPs) are contained in a single dose of mFlusiva, and what is the margin of variance between individual batches or doses of the product? Will the public be informed about the specific number of lipid nanoparticles?
16 ► How many mod-mRNA sequences are contained within a single LNP, and what is the range of variance? Will the public be informed about this specific number of mod-mRNA sequences?
17 ► Has the manufacturer of mFlusiva investigated the role of exosomes in the body of the gene-therapy recipient regarding the systemic distribution of the mod-mRNA gene therapeutic or the pharmacologically active, vaguely glycoprotein-like substance generated within the body?
18 ► Are regulatory authorities warning the population about the exosomal dissemination of mFlusiva or the virus-surface-protein-like toxic substance generated within the human body (shedding)?
19 ► How are pregnant women and the general public being informed about the risk of mFlusiva crossing the placental barrier?
20 ► Will you issue a formal recommendation and warning against treating pregnant women, potentially pregnant women, girls past menarche, and pre-menopausal women with mFlusiva, due to the risk that mFlusiva may penetrate potentially any cell of the unborn child via the placenta and umbilical cord, causing harm or death?
21 ► Why is there no adjustment of the mod-mRNA dose or the pseudo-surface protein produced within the body according to the body weight of the respective recipient?
22 ► Will the public be informed that the toxic mod-mRNA from mFlusiva will remain in the tissue or blood of the recipient for many months, and the toxic hemagglutinin-surface-protein-like proteins formed within the body may persist for one or two years?
23 ► Membrane lipids are lipids found in biomembranes, such as the cell membrane, which provide stability, flexibility, and semi-permeability. The cell membrane consists of lipids and proteins that isolate each cell from its environment, enabling the maintenance of its internal, vital environment. The four lipids in mFlusiva are SM-102, DMG-PEG 2000, DSPC, and cholesterol. Is there a risk that the integrity of vital membranes throughout the recipient’s body could be compromised by the incorporation of these synthetic lipids?
24 ► Is there a risk of damage to cellular organelles, such as mitochondria, in individuals treated with mFlusiva?
25 ► Redactions (censorship bars) in contracts and protocols regarding mFlusiva or its individual components would undermine human dignity, the concept of the informed citizen, and the principle of informed consent. Will you advocate for all documents concerning mRNA-1010 to be made publicly accessible without any redactions or Redaction Codes such as (b) (4) or (b) (6)?
26 ► Does the toxic, vaguely virus-surface-protein-like protein produced within the body of the treated (“vaccinated”) individual accumulate in the brain, nervous tissue in general (such as around myoneural synapses/motor endplates), or the female or male gonads?
27 ► According to the EU Risk Management Plan for Spikevax (Page 32 of 195), the offspring of female Sprague-Dawley rats treated with elasomeran (manufactured by Moderna) exhibited skeletal malformations, specifically skeletal variations consisting of wavy ribs and increased nodules. Are similar skeletal malformations to be expected in human offspring following the treatment of a pregnant woman with mFlusiva (mRNA-1010)?
28 ► Immune privilege means that certain cell types cannot be recognized and destroyed during an immune response. Immune-privileged cells offer pathogens and tumors an opportunity for immune evasion. Various human cell types and tissues possess a form of immune privilege – such as testicular tissue, hair follicles and nail beds, keratinocytes, the cornea, the placenta and fetus, neurons, and stem cells – and cannot be recognized and destroyed by parts of the immune system. What happens to these immune-privileged cells after their transfection with the mod-mRNA (modRNA) of mFlusiva, and what happens after their transfection with bacterial DNA or intact plasmids that may have remained in mFlusiva accidentally or negligently for cost-saving reasons?
29 ► Depending on the human body environment, organ environment (which are subject to individual variation), and the electrostatics (zeta potential) of the LNP, lipid nanoparticles (LNPs) coat themselves with a covering (corona). This has consequences for the organs and tissues targeted preferentially, the capacity to migrate through capillaries, and the risk of clumping. Has this been sufficiently investigated?
30 ► Experimental substances based on mod-mRNA (modRNA) require a very precisely calibrated surface charge – a zeta potential of, for example, –3.13 mV (minus 3.13 millivolts) – in order to avoid or reach specific cell types or organ tissues, such as nerve cells or the gonads. Is the zeta potential of every batch of mFlusiva permanently monitored and publicly disclosed?
31 ► The recognizably unsuitable, yet expectedly harmful or lethal experimental substance mFlusiva (mRNA-1010) also contains the four excipients SM-102 (Ionizable Amino Lipid), DMG-PEG 2000 (PEGylated Lipid), DSPC (Phospholipid), and cholesterol. Do the four lipids SM-102, PEG2000-DMG, DSPC, or cholesterol in mFlusiva correspond to a pharmaceutical grade, or merely a technical or food-grade quality?
32 ► Are the nanolipids SM-102, PEG2000-DMG, DSPC, or cholesterol listed in the Classification and Labelling Inventory (C&L Inventory) of the European Chemicals Agency (ECHA)?
33 ► Do the four nanolipids SM-102, PEG2000-DMG, DSPC, or cholesterol contained in mFlusiva comply with the requirements of the Ph. Eur. (European Pharmacopoeia)?
34 ► Which hazard classes according to Regulation (EC) No 1272/2008 (CLP) correspond to the nanolipids contained in mFlusiva? Please provide a breakdown for SM-102, PEG2000-DMG, DSPC, and cholesterol.
35 ► Which hazard classes according to Regulation (EC) No 1272/2008 (CLP) correspond to the so-called “vaccine” mFlusiva – which is ultimately injected into human bodies and contains a mod-mRNA (modRNA, “mRNA”) with the objective of transfecting hundreds of millions of cells?
36 ► Six and a half years ago, perpetrators and their followers began to establish a totalitarian system under the guise of combating an alleged coronavirus pandemic. The vaccination of several billion people was the objective from the very beginning. To enforce human obedience, individuals were tormented with masks, and even children and adolescents were tortured with these forced masks. People – including children, pregnant women, the sick, and the elderly – were nasopharyngeally raped with pointless tests. School closures, contact bans, and curfews all served to drive people toward the injection needle, experimentally abusing or destroying (via foreign protein presentation and subsequent immune attack) potentially every body cell through transfection with products such as Spikevax (mRNA-1273, elasomeran). Spikevax is a harmful and life-threatening fraud that should never have been approved, let alone administered. Is your department assessing the extent to which mFlusiva is currently profiting from the medical crime of Spikevax at that time?
37 ► Regarding mFlusiva, has your department cooperated directly or indirectly with the CCP (Johns Hopkins Center for Communication Programs, specifically the COVID Behaviors Dashboard), with the IVAC (International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health), with the Behavioral and Cultural Insights (BCI) Unit at the WHO Regional Office for Europe, or with the psychologist and professor of health communication Prof. Dr. Cornelia Betsch (University of Erfurt, member of the Technical Advisory Group on Behavioural and Cultural Insights for Health (TAG-BCI) of the WHO Regional Office for Europe)?
38 ► Presenting the desired antibodies detected in the blood as a metric for the suitability, meaningfulness, and success of an immunization campaign directed against a viral pathogen of the human respiratory tract is pointless and possibly intentionally fraudulent, because what truly matters is mucosal immunity. Do you plan to alter the route of administration from the current (foreseeably harmful or lethal) mod-mRNA injection to a future mFlusiva nasal spray?
39 ► “Durability of RSV-A and RSV-B Neutralizing Antibody Response with mRNA-1345 and Revaccination · Study 101 – Adults 65-79 Years.” It is primarily in this direction that Rituparna Das (Overview of Moderna’s Investigational RSV Vaccine (mRNA-1345) in Adults ≥ 60 Years of Age) (2024) guides the global public, luring unsuspecting or additionally frightened people into the mod-mRNA injection. According to Dr. Das, MD, PhD – who three years ago was Moderna’s vice president for clinical development of COVID-19 vaccines – antibody levels that decline slowly at best, and remain as high as possible, are supposed to guarantee the desired and necessary protection against the RS virus. From your department’s perspective, could confirmed antibody titers against one or more of the three influenza strains targeted by the trivalent mFlusiva – which do not decline after a few weeks but remain high for months or even permanently in treated individuals – be a possible indication that an integration of genetically modified plasmids originating from Escherichia coli into human cells, or of mod-mRNA into the human genome, has occurred?
40 ► Exceptionally, this question shall not consider stem cells (regarding these, see Question 41) and cancer cells (cf. Question 42). Solely because the uridine nucleoside was entirely replaced by N1-methylpseudouridine (abbreviated m1Ψ), the mechanism of action of Comirnaty is referred to not in terms of spikes, but pseudo-spikes; correspondingly, regarding mFlusiva, it refers to a pseudo-surface protein formed within the recipient’s body – a mock version of the surface glycoprotein, more precisely, a mock version of the hemagglutinin (HA protein) of the influenza virus. How do CD8+ T cells, CD4+ T cells, and IgGs react to the simulation of a flu virus surface protein formed within the framework of mFlusiva treatment following the transfection of countless human cells, as soon as this foreign protein and any mFlusiva-induced peptide (a molecule composed of amino acids that can function as a signaling or messenger substance; many hormones, for instance, are peptides) have reached the cell surface?
41 ► How do CD8+ T cells, CD4+ T cells, and IgGs react to the surface proteins and peptides (tiny chains of amino acids, usually consisting of only 2 to 50 building blocks) formed within the framework of mFlusiva treatment following the transfection of human stem cells, as soon as these have reached the cell surface? Does the body of the individual treated with mFlusiva destroy a portion of its vital stem cells, which may be only partially protected by their inherent immune privilege?
42 ► How do CD8+ T cells, CD4+ T cells, and IgGs react to cancer cells that produce pseudo-surface proteins after mFlusiva treatment, as soon as these reach the cell surface along with other peptides? Will mFlusiva inadvertently eradicate cancer, or will the malignant cells – which are effectively operating under the immunological radar – be transformed into a permanent surface-protein factory following their transfection with the mod-mRNA of mFlusiva?
43 ► Influenza viruses do not utilize the ACE2 receptor as an entry portal into the host cell; instead, they use their envelope protein hemagglutinin to bind to sialic acids on the surface of respiratory cells. Practically all cells in the human body carry sialic acids on their surface. Sialic acids are a group of sugars (derivatives of neuraminic acid) that serve as building blocks on the outer edges of cell membranes and proteins. They regulate cell communication, protect cells from death, and serve as docking sites for pathogens. Sialic acids are located there as terminal building blocks of sugar chains (glycans) on glycoproteins and glycolipids, forming an essential part of the cellular protective layer of the glycocalyx. Does your department possess any information as to whether the protein formed within the body of the individual treated with mFlusiva – which vaguely resembles the virus surface protein – damages the surface of the vast array of diverse cells presenting sialic acids? Is this information contained in the product package leaflet and the patient information sheet? Are the administering (“vaccinating”) physicians informed accordingly, and is this knowledge reflected in medical consultations?
44 ► Crucial cell types within the testes include Leydig cells (LC), Sertoli cells (SC), spermatogonia (Spg), and various developmental stages of sperm. Does your department possess any information as to whether the protein formed within the body of the individual treated with mFlusiva – which vaguely resembles the virus surface protein – destroys or damages Leydig cells (LC), Sertoli cells (SC), spermatogonia (Spg), and various developmental stages of sperm? Is this information contained in the product package leaflet and the patient information sheet? Are the administering (“vaccinating”) physicians informed accordingly, and is this knowledge reflected in medical consultations?
45 ► What findings does your department possess regarding a damaging or destructive effect of mFlusiva on oocytes (synonyms: oocyte, ovocytus, egg, egg cell, ovum) resulting from the transfection of body cells and the synthesis of a foreign protein?
46 ► What findings does your department possess regarding oocytes and a damaging or destructive effect of the pseudo-surface proteins that are generated within the body of the female individual treated with mFlusiva?
47 ► What findings does your department possess regarding a damaging or destructive effect of mFlusiva on the tissues of the ovaries, uterus, vagina, and placenta resulting from the transfection of body cells and the synthesis of a foreign protein?
48 ► What findings does your department possess regarding the body cells within the tissues of the ovaries, uterus, vagina, and placenta and a damaging or destructive effect of the pseudo-surface proteins generated within the body of the female individual treated with mFlusiva?
49 ► The elastic fiber (yellow fiber) imparts elastic properties to tissue. Elastic fibers are stretchable fibers of the extracellular matrix of connective tissue produced by fibroblasts. Elastic fibers consist of two clearly distinguishable components: an elastin core and the surrounding microfibrils, which are composed of fibrillins and other proteins such as fibulin-5. Fibulin-5 mediates the connection of the elastic fibers in the extracellular matrix to the surrounding cells by binding to integrins. Elastin is responsible for the characteristic property from which elastic fibers derive their name. The individual elastin monomers are linked by covalent bonds via up to 4 lysine side chains each, forming random coil structures that play a crucial role in the elasticity of the elastic fibers. Due to their high resilience, this fiber type is predominantly found in tissues subjected to severe tensile stress, which include, for example, elastic ligaments, elastic cartilage, arteries and veins (particularly in the larger arteries, such as within both the membrana elastica interna and the membrana elastica externa), the gallbladder, lungs, vocal cords, and skin. They can extend their baseline length by 150 percent through stretching – for instance, by the contraction of smooth muscle cells – and revert to their original length once the force is removed. The tensile strength of elastic fibers is approximately 300 N/cm². As a result of degenerative processes, the elasticity of elastic fibers declines with age. Aortic rupture refers to the tearing (rupture) of the vascular wall of the main artery (aorta). To what extent does mFlusiva damage or destroy elastic fibers, such as those in the arteries or the skin? What information does your department possess regarding the occurrence of aortic rupture following „vaccination“ with mFlusiva?
50 ► Mitochondrial inheritance (synonyms: mitochondrial pedigree, extrachromosomal inheritance) implies that the affected genes are not located on the chromosomes within the cell nucleus, but within the mitochondria. According to the current state of science, mitochondrial DNA (mtDNA) in humans appears to be inherited exclusively maternally. In eukaryotic cells – that is, all cells featuring a nucleus – coding DNA is found not only in the nuclear genome but also within the mitochondria. This is referred to as a mitochondrial genome or mitochondrial DNA (mtDNA). The mtDNA is a circular double strand with a size of approximately 16.5 kb (kilobases), existing in 2 to 10 copies per mitochondrion. Many eukaryotic cells contain more than 1,000 mtDNA molecules distributed across hundreds of mitochondria. The mature oocyte often contains more than 100,000 copies of mtDNA, meaning that mtDNA accounts for up to one-third of the total DNA of a mature egg cell. The mtDNA molecule contains a total of 37 genes, 13 of which code for proteins of the respiratory chain (oxidative phosphorylation). The remaining 24 genes code for 22 tRNA and 2 rRNA molecules, which are indispensable for the protein biosynthesis of the 13 mitochondrially encoded polypeptides. (In contrast, all other mitochondrial proteins are nuclear-encoded and are transported into the mitochondria following cytosolic synthesis. Of the 74 proteins of the respiratory chain [74 out of 87], a large portion is encoded by the nuclear genome.) What findings does your department possess regarding a damaging or destructive effect of mFlusiva on mitochondrial inheritance resulting from the transfection of body cells and the synthesis of a foreign protein?
51 ► What findings does your department possess regarding mitochondrial inheritance and a damaging or destructive effect of the pseudo-surface proteins generated within the body of the individual treated with mFlusiva?
52 ► Epigenetics studies those alterations in gene function that do not involve changes to the underlying deoxyribonucleic acid (DNA) sequence – such as through mutation or recombination – yet are still passed on to daughter cells. Acetylation of crucial promoter sites for inflammatory genes, which falls within the domain of epigenetics, renders specific genes more accessible for transcription, thereby amplifying their effects. Cf., e.g., Alexander Simonis, et al.: “We were able to demonstrate that SARS-CoV-2 mRNA vaccination establishes extensive and persistent H3K27ac at promoters of short-lived macrophages.” (Persistent epigenetic memory of SARS-CoV-2 mRNA vaccination in monocyte-derived macrophages. Mol Syst Biol. 2025 Apr;21(4):341-360.) In this context, H3K27ac denotes the acetylation of the lysine residue at the N-terminal position 27 of the histone H3 protein (a histone being a DNA packaging protein). However, such phenomena by no means inherently lead to greater competence of the immune system; rather, they can induce an uncontrolled inflammatory state as well as the activation of oncogenes, potentially leading to cancer and perhaps even hyper-progressive cancer (“turbo cancer”). The hallmarks of hyper-progressive cancer include: an unusually high proliferation rate, the simultaneous emergence and growth of multiple independent tumor foci within the same organ (such as the female breast), a frequent occurrence of these aggressive forms of cancer in atypically young patients (e.g., aged between 30 and 49 years), as well as extremely rapid relapses (recurrences) and metastasis. Does mFlusiva lead to a hypersensitization of the inflammatory axis of the immune system, thereby placing treated (“vaccinated”) individuals at substantial health risk from various inflammatory reactions and autoimmune attacks, as well as the life-threatening risk of tumor formation accompanied by potentially rapid tumor growth?
53 ► “Histones primarily serve to package DNA. A DNA molecule ‘compressed’ by histones is approximately 40,000 times more compact than unpackaged DNA. Furthermore, histones perform an important function in the regulation of gene expression and DNA repair. Histones undergo post-translational modification, which influences their interaction with DNA. Histones H3 and H4 possess long molecular tails that project from the nucleosome and can be modified at various positions by covalently bound groups. These various possible alterations likely constitute a distinct code – the histone code – which controls the transcription of genetic information and forms part of the epigenetic code.” (flexikon.doccheck.com/de/Histon) “Post-translational modification can alter the properties of a protein. The addition of charged groups such as phosphate groups, or hydrophobic molecules such as lipids, can, for example, alter the binding properties of a protein to other proteins or membranes. Given that many modifications are reversible, a targeted and short-term interaction between different cellular components can be induced in this manner. Consequently, post-translational modifications play a special role in, for example, signal transduction and are generally of significance for the function and activity of proteins.” (flexikon.doccheck.com/de/Posttranslationale_Modifikation) Does mFlusiva impair the interaction between histones and DNA? Does mFlusiva impair the regulation of gene expression or DNA repair?
54 ► Cellular senescence describes a phenomenon in which cells cease to divide. Leonard Hayflick and Paul Moorhead discovered that normal human fetal fibroblasts in culture achieve a maximum of approximately 50 cell population doublings before aging. Mechanistically, cellular senescence can be triggered by an alteration in DNA resulting from the shortening of telomeres during each cell division process. In this specific scenario, it is referred to as replicative senescence. However, cells can also be driven into senescence independently of the number of cell divisions – for instance, via DNA damage in response to elevated reactive oxygen species (ROS), through the activation of oncogenes, or via cell-cell fusion. The number of senescent cells in tissue increases significantly during normal aging. The senescence-associated secretory phenotype (SASP) describes the release of pro-inflammatory molecules by cells that have transitioned into senescence. These cells have reached cell cycle arrest, frequently as a consequence of stressors such as DNA damage, telomere shortening, or oncogenic signaling. Among the released molecules are cytokines, growth factors, and proteases. These promote inflammatory reactions and activate immune cells, which can subsequently recognize and remove the senescent cells. They support intercellular communication and contribute to tissue repair, but can also facilitate chronic inflammation and age-related diseases. The SASP is associated with many age-related illnesses, including type 2 diabetes and atherosclerosis. Can the SASP also be a consequence of the administration of mFlusiva – for example, as a result of an accumulation of that mock version (an object intended to mislead) of a hemagglutinin (HA) surface protein, which following transfection is produced by an unknown number of the recipient’s body cells at an unknown quantity over many weeks or months, within individual organs and throughout the entire body? What other findings regarding a potential correlation between mFlusiva and cellular senescence does your department possess? Does mFlusiva generate chronic inflammation or age-related diseases?
55 ► Does your department hold the view that medical personnel, and indeed all persons present in the same room, should have worn protective goggles, gloves, laboratory coats, and face masks when drawing up the syringes as well as during the injection of mFlusiva?
56 ► Does your department hold the view that cleaning staff disposing of the syringes, as well as waste management workers destroying unused remnants of mFlusiva, must wear protective goggles, gloves, laboratory coats, and face masks?
57 ► How does your department plan and monitor that any remnant of expired or otherwise unused mFlusiva is transferred to a waste incineration plant suitable for destroying lipid nanoparticles (LNPs) loaded with mod-mRNA (modRNA) and capable of transfecting human cells, rather than entering household waste or the sewerage system?
58 ► From your department’s perspective, is it not long overdue to warn all healthcare workers against the substance mFlusiva and all other so-called “vaccines” based on a mod-mRNA (modRNA) administered in Canada since 14 December 2020?
59 ► From your department’s perspective, is it not long overdue to warn all military personnel against the substance mFlusiva and all other so-called “vaccines” based on a mod-mRNA (modRNA)?
60 ► In your department’s view, what is the relationship between the invention, the funding of research, the technical aspect of production, the financing of production, the approval, the promotion in broadcasting and the press, and ultimately the injection of the so-called “vaccine” mFlusiva – which might not exist without a fraudulently fueled epidemic panic and a subsequent, lavishly funded vaccine advertising campaign surrounding products such as Comirnaty and Spikevax – and the simulation exercises Dark Winter (2001), Atlantic Storm (2005), SPARS Pandemic 2025–2028 (2017), Clade X (2018), and Event 201 (2019)? What role does the text by Neil M. Ferguson, et al. (Strategies for mitigating an influenza pandemic (Nature. 2006 Jul 27;442(7101):448-52. doi: 10.1038/nature04795.) play for the substance mFlusiva?
61 ► On 12 January 2017, the generous Defense Advanced Research Projects Agency (DARPA) of the Department of Defense (DoD) announced with enthusiasm: “moderna tx. has begun Phase I trials of DARPA-funded mRNA-1325 Zika vaccine and cleared to begin trials of mRNA-1388 Chikungunya vaccine.” (x.com/DARPA/status/819556371213484032) What is the distance between the invention, the funding of research, the technical aspect of production, the financing of production, the approval, the promotion in broadcasting and the press, and ultimately the injection millions of times over of the so-called “vaccine” mFlusiva – which might not exist without a fraudulently fueled epidemic panic and a subsequent, lavishly funded vaccine advertising campaign surrounding the product Spikevax – and the Defense Advanced Research Projects Agency or Matthew (Matt) Hepburn, the program manager for DARPA between 2013 and 2019?
62 ► Human beings encounter the environment – the world – accompanied by viruses and through viruses. For millennia, for tens of millennia, humans and common cold viruses have, on the whole, coexisted very well. Children become strong and adults remain so, not in spite of, but because they pass common cold viruses, and thereby also influenza viruses, to one another. To be a human among humans means to receive viruses, as well as to distribute them. This coexistence of virus and Homo sapiens is an evolutionary success story. When will you explain to the public that successfully managing the threat posed by influenza viruses by no means depends on introducing a mod-mRNA (modRNA) into the human body, but rather on a sufficiently high vitamin D level, particularly for our older citizens and for all people living at a higher latitude (at a relatively great distance from the equator), as well as on freedom from the fear of becoming infected and on regular human-to-human interaction – the latter occurring precisely not via microphones and loudspeakers or via the screens of PCs or TVs, but through shared conversation, dining, singing, or listening to music, attending the theater together, or playing sports?
63 ► What is the relationship between the development and approval of the mFlusiva “vaccine” and the activities of the EcoHealth Alliance (formerly led by Peter Daszak) or the gain-of-function research conducted by Ralph Baric?
64 ► “A man who is born into a world already possessed, if he cannot get subsistence from his parents on whom he has a just demand, and if the society do not want his labour, has no claim of right to the smallest portion of food, and, in fact, has no business to be where he is. At nature’s mighty feast there is no vacant cover for him. She tells him to be gone, and will quickly execute her own orders, if he does not work upon the compassion of some of her guests. If these guests get up and make room for him, other intruders immediately appear demanding the same favour. The report of a provision for all that come, fills the hall with numerous claimants. The order and harmony of the feast is disturbed, the plenty that before reigned is changed into scarcity; and the happiness of the guests is destroyed by the spectacle of misery and dependence in every part of the hall, and by the clamorous importunity of those, who are justly enraged at not finding the provision which they had been taught to expect. The guests learn too late their error, in counter-acting those strict orders to all intruders, issued by the great mistress of the feast, who, wishing that all guests should have plenty, and knowing she could not provide for unlimited numbers, humanely refused to admit fresh comers when her table was already full.” Thomas Robert Malthus, An Essay on the Principle of Population, 2nd edition, published in 1803. Does your department endorse the worldview and recommendations for action of Thomas Robert Malthus (1766 – 1834), and does the so-called “vaccine” mFlusiva, based on a mod-mRNA (modRNA), serve the goal of reducing the global population—an objective that has unfortunately been highly esteemed in many circles in the USA for 200 years?
65 ► Francis Galton, fascinated by the work of his uncle Charles Darwin (On the Origin of Species) asked: “Could not the race of men be similarly improved? Could not the undesirables be got rid of and the desirables multiplied?” In 1883, he coined the term eugenics and advocated for perfecting humanity through selective breeding (better breeding). Soon after, his followers linked this newly invented category of “undesirables” to all kinds of problems and, in order to create an advanced and superior race, demanded state measures to improve the overall “biological quality” of society. In 1907, Galton co-founded the Eugenics Society. Does your department endorse the worldview and recommendations for action of Francis Galton (1822–1911), and does the so-called “vaccine” mFlusiva – which is inherently ineffective and otherwise harmful or lethal – serve the goal of reducing the fertility and the number of children of selected individuals or groups of people by means of extensive or complete castration or sterilization, the transfection of the body cells of both the mother and the unborn child, and accompanied by a conspicuous increase in the number of involuntary abortions and stillbirths, for instance through the prioritized and repeated “vaccination” of members of ethnic minorities, of people in sub-Saharan Africa, of the chronically ill, people with rare diseases, people with disabilities, or elderly people?
66 ► The text published on 31 January 2020 by Prashant Pradhan, et al. (Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag. doi: doi.org/10.1101/2020.01.30.927871.) was swiftly withdrawn by the authors. It and the fierce criticism directed against it could be two important stepping stones toward understanding and achieving the necessary, comprehensive (scientific, social, and legal) re-evaluation of the so-called “COVID-19 pandemic”, particularly regarding that political guideline which deemed it useful and even necessary to treat all of humanity, for the purpose of an anticipated prophylaxis, with hastily manufactured substances, such as a modRNA (mod-mRNA). Here is the abstract from that time. “We are currently witnessing a major epidemic caused by the 2019 novel coronavirus (2019-nCoV). The evolution of 2019-nCoV remains elusive. We found 4 insertions in the spike glycoprotein (S) which are unique to the 2019-nCoV and are not present in other coronaviruses. Importantly, amino acid residues in all the 4 inserts have identity or similarity to those in the HIV-1 gp120 or HIV-1 Gag. Interestingly, despite the inserts being discontinuous on the primary amino acid sequence, 3D-modelling of the 2019-nCoV suggests that they converge to constitute the receptor binding site. The finding of 4 unique inserts in the 2019-nCoV, all of which have identity/similarity to amino acid residues in key structural proteins of HIV-1 is unlikely to be fortuitous in nature. This work provides yet unknown insights on 2019-nCoV and sheds light on the evolution and pathogenicity of this virus with important implications for diagnosis of this virus.” What is your position on the 2020 abstract by Prashant Pradhan, et al. (doi.org/10.1101/2020.01.30.927871), which identified similarities between the COVID-19 spike protein and HIV, the COVID-19 lab leak theory, and what conclusions do you draw regarding the use of mFlusiva?
·
·
·
·
Reactions
·
·
·
·
From: hcminister.ministresc ( hcminister.ministresc @ hc-sc.gc.ca )
To: Edward von Roy
25.08.2026 04:01:13
Open Letter to the Minister: 66 Questions about mFlusiva (mRNA-1010)
On behalf of the Honourable Marjorie Michel, Minister of Health, thank you for taking the time to write.
Please be assured that your correspondence is being carefully reviewed.
The Minister greatly appreciates receiving the views of Canadians on matters that are important to them.
Again, thank you for writing.
Executive Correspondence Division
·
Au nom de l’honorable Marjorie Michel, ministre de la Santé, merci d’avoir pris le temps d’écrire.
Sachez que votre correspondance sera examinée attentivement.
La ministre est très sensible aux points de vue des Canadiennes et des Canadiens sur les questions qui leur tiennent à cœur.
Encore une fois, merci d’avoir écrit.
Division de la correspondance de la haute gestion
·
·
·
·
BRDD DGO Enquiries (HC/SC)
Die Abkürzung BRDD DGO Enquiries (HC/SC) steht für die zentrale Anlaufstelle für Anfragen (Enquiries) des Director General’s Office (DGO) der Biologic and Radiopharmaceutical Drugs Directorate (BRDD) innerhalb von Health Canada / Santé Canada (HC/SC).
Als oberste Management- und Koordinationsebene dieser Regulierungsbehörde erstrecken sich die Zuständigkeiten, Verpflichtungen und Befugnisse auf nationaler Ebene (für ganz Kanada) sowie intern (innerhalb von Health Canada) auf folgende Kernbereiche:
Zuständigkeiten und Aufgabenbereiche (jurisdiction)
Die BRDD ist als kanadische Bundesbehörde landesweit für die Überwachung und Zulassung hochspezifischer medizinischer Produkte zuständig. Das DGO steuert und koordiniert hierbei die strategische Ausrichtung für folgende Produktklassen:
• Biologika (Schedule D Drugs): Impfstoffe, Blut- und Blutprodukte, Biotherapeutika, Gen- und Zelltherapien.
• Radiopharmazeutika (Schedule C Drugs): Medizinische Isotope und radioaktive Arzneimittel für Diagnostik und Therapie.
• Menschliche Zellen, Gewebe und Organe (CTO): Regulierung von Transplantaten.
• Reproduktionsmedizin: Durchsetzung und Überwachung von Bestimmungen des Assisted Human Reproduction Act.
Befugnisse (authorities)
Das Director General’s Office (DGO) besitzt weitreichende administrative und regulatorische Entscheidungsbefugnisse:
• Zulassungskompetenz: Das DGO erteilt die finalen behördlichen Genehmigungen für das Inverkehrbringen (Verkauf) von verschreibungspflichtigen biologischen und radiopharmazeutischen Arzneimitteln in ganz Kanada.
• Genehmigung klinischer Studien: Befugnis zur Freigabe oder regulatorischen Sperrung von klinischen Prüfungen (clinical trials) der Phasen I bis III für Biologika und Radiopharmazeutika auf kanadischem Boden.
• Durchsetzung von Richtlinien: Das DGO besitzt die regulatorische Autorität, verbindliche Standards, Qualitätsmanagementsysteme (nach ISO-Normen) und behördliche Leitfäden (Guidance Documents) zu erlassen.
Verpflichtungen (obligations)
Die Anlaufstelle für Anfragen (enquiries) dient der Erfüllung der gesetzlichen und behördlichen Pflichten zur Transparenz und Kommunikation:
• Schnittstelle für Stakeholder und Industrie: Verpflichtung zur Durchführung von Pre-Submission-Meetings und wissenschaftlichen Beratungen mit Pharmaherstellern (sponsors), um regulatorische Anforderungen für Marktzulassungen transparent zu klären.
• Public Relations und Bürgerinformation: Beantwortung offizieller Anfragen der kanadischen Öffentlichkeit, von Patientengruppen sowie Medien zu regulatorischen Entscheidungen, Arzneimittelsicherheit und Zulassungsstatus.
• Berichterstattung und Governance: Interne Verpflichtung, die Arbeit der Direktion an die übergeordneten Ebenen der Health Products and Food Branch (HPFB) sowie direkt an das kanadische Gesundheitsministerium zu melden.
• Internes Qualitätsmanagement: Verpflichtung zur Durchführung interner Audits und zur Standardisierung von Betriebsabläufen (Standard Operating Procedures, SOPs) zur Einhaltung internationaler und nationaler Sicherheitsstandards.
(E. v. R.)
·
·
·
·
Health Canada’s response regarding – mRNA-based influenza vaccine
BRDD DGO Enquiries (HC/SC) [ brdd.dgo.enquiries @ hc-sc.gc.ca ]
08.10.2026 16:07
Dear Edward von Roy,
Please find attached a letter response to your correspondence of August 24, 2026, where you expressed your concerns regarding the investigational messenger RNA (mRNA)-based influenza vaccine, mFlusiva (also designated as mRNA-1010). Your letter was forwarded to the Biologic and Radiopharmaceutical Drugs Directorate of Health Canada for response.
Sincerely,
BRDD
·
·
·
·
Health Canada – Health Products and Food Branch
Santé Canada – Direction générale des produits de santé et des aliments
Biologic and Radiopharmaceutical Drugs Directorate (BRDD)
Eglantine Driveway
LCDC Building
Ottawa, Ontario
Canada
·
Edward von Roy
Graduate Social Worker, University of Applied Sciences (Diplom-Sozialarbeiter / Sozialpädagoge, FH)
Mönchengladbach
Germany
·
October 8, 2026
·
Dear Edward von Roy,
Thank you for your correspondence of August 24, 2026, addressed to the Honourable Majorie Michel, Minister of Health, where you expressed your concerns regarding the investigational messenger RNA (mRNA)-based influenza vaccine, mFlusiva (also designated as mRNA-1010). Your letter was forwarded to the Biologic and Radiopharmaceutical Drugs Directorate of Health Canada for response.
Health Canada is the federal regulator responsible for the review and authorization of vaccines for use in Canada. We can confirm that the New Drug Submission (NDS) for mRNA-1010 (proposed brand name: mFlusiva) is currently under review by Health Canada. The submission was filed in January 2026 and is listed on Health Canada’s Drug and health product submissions under review (SUR) – Canada.ca webpage.
As outlined in Health Canada’s guidance document on the Management of Drug Submissions and Applications, the standard review timeline for this type of submission is 300 days. However, review timelines may be extended when additional information, analyses, or clarification are required to support a comprehensive scientific assessment. At this time, mFlusiva has not yet been authorized in Canada.
mRNA vaccines, such as mFlusiva, contain genetic instructions that allow cells near the injection site to temporarily produce a protein found on the surface of a virus. The mRNA from the vaccine is rapidly broken down by the body after the protein is produced. The immune system recognizes this protein as foreign and develops an immune response, including antibodies and immune memory. If the person is later exposed to the virus, the immune system can respond more quickly and effectively. This mechanism is temporary and differs from gene therapy, which generally aims to achieve long-term expression of a gene or protein to treat or correct a disease.
Like all vaccines, mRNA vaccines work by exposing the immune system to a harmless component that enables the body to recognize and respond to a disease-causing agent without causing the disease itself.
As the submission for mFlusiva (mRNA-1010) remains under review, details contained within the submission package, as well as communications between Health Canada and the manufacturer, are considered confidential business information and cannot be disclosed.
Nevertheless, we are pleased to provide general information about the Health Canada review process for any new vaccine. Before a vaccine can be authorized in Canada, manufacturers must submit extensive scientific evidence demonstrating the vaccine’s safety, efficacy, and quality. Health Canada’s review is conducted under the requirements of the Food and Drugs Act and its Regulations. The regulatory requirements are informed by science and are aligned with international standards, including the International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use and the World Health Organization (WHO) guidelines on the clinical and quality evaluation of vaccines.
The evidence submitted in support of vaccine authorization generally falls into three main categories:
1. Non-clinical (pre-clinical) evidence
Before testing in humans begins, vaccines undergo laboratory and animal studies using products representative of those intended for human use. These studies are designed to demonstrate:
• Safety, including toxicity testing and evaluation of potential adverse effects.
• Immune response, showing that the vaccine can stimulate an appropriate immune response against the target pathogen.
2. Evidence of manufacturing quality
Manufacturers must provide evidence showing that:
• Manufacturing complies with Good Manufacturing Practices (GMP), including facility inspection.
• Manufacturing processes consistently produce vaccine lots that meet established quality and purity specifications.
• Product quality is maintained through the definition of proper storage and transportation conditions.
• Appropriate controls are in place to ensure the vaccine is free from contaminants, including continuous monitoring and measurement.
3. Clinical evidence (safety and efficacy)
Clinical studies are conducted in the populations expected to receive the vaccine, which may include adults, older adults, children, and pregnant individuals, as appropriate. Note that the population described in the indication for an authorized vaccine generally reflects the population studied in the clinical trial included in the submission package.
Clinical trials must be conducted according to Good Clinical Practice (GCP) standards and are designed to demonstrate:
• Vaccine safety, including that the proposed dose is safe and well tolerated, with no evidence of enhanced disease.
• Vaccine efficacy, including a demonstration that the vaccine induces an appropriate immune response (immunogenicity) and provides protection against disease.
Demonstrating vaccine efficacy requires:
• A strong understanding of virus characteristics and a reliable definition of the disease caused by viral infection.
• Validated assays to assess the magnitude, characteristics and quality of the immune response.
• Carefully defined clinical endpoints and enrollment of large numbers of participants, often numbering in the tens of thousands, to provide sufficient evidence regarding vaccine performance.
Health Canada reviews all submitted evidence to determine whether the vaccine meets the required standards for safety, efficacy, and quality and whether its benefits outweigh its risks. For more information please visit: How Drugs are Reviewed in Canada.
Transparency Following Authorization
Should a vaccine be authorized, Health Canada publishes information to help Canadians understand the basis for its decision.
This includes:
• The Product Monograph, available through the Drug Product Database, which contains information such as approved indications, contraindications, warnings and precautions, dosing and administration instructions, adverse reactions, storage conditions, handling and disposal, etc.
• The Summary Basis of Decision (SBD) that summarizes the scientific assessment conducted by Health Canada, including key findings regarding safety, efficacy, and quality. It also includes information on pharmacovigilance activities and risk mitigation measures as part of the Risk Management Plan.
• Additional information on drugs, including vaccines can also be found on the Health Canada’s Drug and Health Product Portal.
If a manufacturer wishes to introduce a new route of administration after a drug has been authorized, it must file a Supplement to a New Drug Submission (SNDS) to Health Canada for review, together with the supporting scientific data.
Independent Recommendations on Vaccine Use
Following authorization of a vaccine, the National Advisory Committee on Immunization (NACI) reviews the available evidence and issues recommendations regarding the optimal use of the vaccine in Canada. NACI is an independent expert advisory committee whose members represent a range of disciplines, including public health, infectious diseases, immunology, pediatrics, epidemiology, and other relevant specialties.
Ongoing Monitoring After Authorization
Health Canada’s oversight of the quality and manufacturing of vaccines continues beyond market authorization is granted, through the Lot Release Program which provides an additional check on biologic drugs to help assure ongoing quality and consistency of vaccine production.
Once a vaccine is on the market, Health Canada and the Public Health Agency of Canada (PHAC) share responsibility for monitoring vaccine safety.
This includes:
• Mandatory reporting of serious adverse events by market authorization holders to Health Canada’s Canada Vigilance Program.
• Voluntary reporting from healthcare professionals and consumers.
• Reporting by provincial and territorial public health authorities to PHAC through the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) to monitor the safety of immunization programs.
• Ongoing review of Canadian and international safety data to identify potential safety signals and assess whether any regulatory action may be required.
If new safety information emerges, Health Canada may update the product monograph and take other appropriate regulatory action to protect Canadians.
Health Canada’s Commitment to Science-Based Decision-Making
The health and safety of Canadians are the utmost priority for Health Canada, and that is why we regulate all drugs, including biologic drugs (such as vaccines), based on rigorous standards of evidence. Vaccines are no exception, and, in fact, the standards for vaccines are often higher than for some drugs, as we recognize that they are developed for administration to healthy individuals to prevent disease. More information on these standards and how Health Canada regulates vaccines for human use in Canada can be found on the Regulating vaccines for human use in Canada webpage.
Health Canada recognizes that mis- and disinformation can contribute to misunderstandings about vaccines, including the interpretation of scientific studies and adverse event reporting data. The Government of Canada and the scientists, medical experts, and public health officials who are responsible for reviewing the evidence related to safety, efficacy and quality of vaccines, take the health and safety of Canadians extremely seriously. Regulatory decisions are based on the totality of available scientific evidence and are continually reassessed as new information becomes available.
Health Canada also works in close collaboration with international agencies, including other regulators and the WHO, on the safety and effectiveness of vaccines. Additional information that addresses your concerns is available through a number of reputable websites. Many of those, which include a number in Canada, both national and provincial, are listed by the WHO under the Vaccine Safety Net.
In August 2026, mFlusiva was approved by the United States Food and Drug Administration (US FDA). It is also currently under review by other international regulators, including the European Medicines Agency (EMA) and the Therapeutic Goods Administration (TGA) of Australia. Regulatory decisions in other jurisdictions are considered independently and do not determine Health Canada’s decision, which is based on its own scientific assessment of the evidence submitted by the manufacturer.
We trust that this information is helpful in addressing your questions and concerns regarding mFlusiva and the regulatory assessment of vaccines in Canada.
Yours sincerely,
Sonia Corrent, PhD.,
Director General
·
·
·
·